GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease (SHIELD-2)

This study has been terminated.
(This study was terminated due to the lack of efficacy of GSK1605786A in Crohn's disease based on the results of Study CCX114151.)
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01316939
First received: March 3, 2011
Last updated: March 13, 2014
Last verified: March 2014
  Purpose

A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of two doses (500 mg once daily and 500 mg twice daily) of GSK1605786A in maintaining remission over 52 weeks in adult subjects with Crohn's disease. Efficacy will be assessed by the Crohn's Disease Activity Index (CDAI) score. Eligible subjects will have achieved response (CDAI decrease of at least 100 points) and/or remission (CDAI less than 150) in a prior GSK sponsored induction study. The primary endpoint will be proportion of subjects in remission at both Weeks 28 and 52. Safety will be assessed by recording of adverse events, clinical laboratory parameters including liver function tests, vital signs and electrocardiogram. Population pharmacokinetics will evaluate the two doses of GSK1605786A. Health outcomes assessments will include changes in Inflammatory Bowel Disease Questionnaire (IBDQ), SF-36v2, EQ-5D, Work Productivity and Activity Impairment - Crohn's Disease (WPAI-CD) and disability.


Condition Intervention Phase
Crohn's Disease
Drug: GSK1605786A
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 52 Week Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Remission (CDAI score less than 150 points) [ Time Frame: At both Weeks 28 and 52 ] [ Designated as safety issue: No ]
    Proportion of subjects in clinical remission (CDAI score less than 150 points)


Secondary Outcome Measures:
  • Corticosteroid-free remission [ Time Frame: At both Weeks 28 and 52 ] [ Designated as safety issue: No ]
    Proportion of subjects in clinical remission (CDAI score less than 150 points) and not taking corticosteroids

  • Remission in subjects who were in remission at baseline [ Time Frame: At both Weeks 28 and 52 ] [ Designated as safety issue: No ]
    Proportion of subjects in clinical remission (CDAI score less than 150 points) in subjects who were in remission at baseline

  • Remission at end of treatment [ Time Frame: Week 52 ] [ Designated as safety issue: No ]
    Proportion of subject in clinical remission (CDAI score less than 150 points) at end of treatment

  • Clinical response (CDAI decrease of at least 100 points) [ Time Frame: At both Weeks 28 and 52 ] [ Designated as safety issue: No ]
    Proportion of subjects with clinical response (CDAI decrease of at least 100 points)

  • Induction of remission in subjects who were not in remission at baseline [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    Time to induction of remission in subjects who were not in remission at baseline

  • Change from baseline in CDAI score [ Time Frame: Weeks 4, 8, 12, 20, 28, 36, 44, 52 ] [ Designated as safety issue: No ]
    Change from baseline in CDAI score at various timepoints over the treatment period

  • Safety outcomes [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    Change from baseline in safety measures and incidence of adverse events and serious adverse events

  • Health outcomes [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    Change from baseline in quality of life measures

  • Biomarkers [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    Change from baseline in C-reactive protein and faecal calprotectin


Enrollment: 229
Study Start Date: May 2011
Study Completion Date: September 2013
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Placebo
Drug: Placebo
Placebo
Experimental: GSK1605786A
500 milligrams once daily or twice daily
Drug: GSK1605786A
GSK1605786A 500 milligrams once daily
Drug: GSK1605786A
GSK1605786A 500 milligrams twice daily

Detailed Description:

This is a multi-centre, randomised, placebo-controlled, double-blind parallel group study in adult subjects with Crohn's disease who previously achieved clinical response (CDAI decrease of at least 100 points) and/or remission (CDAI less than 150) in a prior Phase III induction study (Study CCX114151 or another GSK sponsored induction study). Subjects will be randomised to 52 weeks of oral treatment with GSK1605786A 500 mg once daily or 500 mg twice daily or placebo. Subjects who are receiving concomitant corticosteroids at entry will undergo dose tapering following a defined schedule. Subjects who complete the treatment period may be eligible to enter an open-label extension study. Subjects who experience disease worsening and require additional (rescue) treatment will be withdrawn and may be eligible to enter the open-label study. Subjects who do not enter the open-label study must complete a follow-up assessment 4 weeks after completion of treatment. Approximately 756 subjects will be enrolled.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects achieving clinical response (CDAI decrease of at least 100 points) and/or remission (CDAI less than 150) upon completion of treatment in Study CCX114151 or another GSK sponsored induction study
  • Written informed consent prior to any CCX114157 specific study procedures
  • Females of child-bearing potential must be sexually inactive or commit to use of consistent and correct use of contraceptive methods with a failure rate of less than 1 percent
  • Stable doses of Crohn's disease medications
  • Subjects on corticosteroids at entry must be willing to undergo corticosteroid dose taper during the study

Exclusion Criteria:

  • If female, is pregnant, has a positive pregnancy test or is breast-feeding
  • Subjects with known or suspected coeliac disease or a positive screening test (anti-tissue transglutaminase antibodies) should have been excluded from enrolment into the induction studies. Subjects in whom a diagnosis of coeliac disease is subsequently suspected should have this excluded with testing for anti-tissue transglutaminase antibodies prior to enrolment into the maintenance study.
  • Known or suspected fixed symptomatic small bowel stricture
  • Enterocutaneous, abdominal or pelvic fistulae likely to require surgery during the study period
  • Current sepsis or infections requiring intravenous antibiotic therapy for greater than 2 weeks
  • Evidence of hepatic dysfunction, viral hepatitis, or liver function abnormalities
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01316939

  Hide Study Locations
Locations
United States, Arizona
GSK Investigational Site
Little Rock, Arizona, United States, 72205
GSK Investigational Site
Tucson, Arizona, United States, 85712
United States, California
GSK Investigational Site
La Jolla, California, United States, 92093
GSK Investigational Site
San Diego, California, United States, 92103
GSK Investigational Site
San Francisco, California, United States, 94115
United States, Colorado
GSK Investigational Site
Aurora, Colorado, United States, 80045
GSK Investigational Site
Lakewood, Colorado, United States, 80215
GSK Investigational Site
Littleton, Colorado, United States, 80120
United States, Connecticut
GSK Investigational Site
Hamden, Connecticut, United States, 06518
GSK Investigational Site
New Haven, Connecticut, United States, 06510
United States, District of Columbia
GSK Investigational Site
Washington, District of Columbia, United States, 20007
United States, Florida
GSK Investigational Site
Jacksonville, Florida, United States, 32256-6004
GSK Investigational Site
Port Orange, Florida, United States, 32127
United States, Georgia
GSK Investigational Site
Atlanta, Georgia, United States, 30342-5006
GSK Investigational Site
Suwanee, Georgia, United States, 30024
United States, Illinois
GSK Investigational Site
Chicago, Illinois, United States, 60637
United States, Indiana
GSK Investigational Site
Indianapolis, Indiana, United States, 46237
United States, Kentucky
GSK Investigational Site
Lexington, Kentucky, United States, 40536-0298
United States, Louisiana
GSK Investigational Site
Hammond, Louisiana, United States, 70403
GSK Investigational Site
Monroe, Louisiana, United States, 71201
United States, Maryland
GSK Investigational Site
Chevy Chase, Maryland, United States, 20815
GSK Investigational Site
South Towson, Maryland, United States, 21286
GSK Investigational Site
Towson, Maryland, United States, 21204
United States, Massachusetts
GSK Investigational Site
Boston, Massachusetts, United States, 02114
United States, Michigan
GSK Investigational Site
Ann Arbor, Michigan, United States, 48109-5682
GSK Investigational Site
Chesterfield, Michigan, United States, 48047
GSK Investigational Site
Troy, Michigan, United States, 48098
United States, Minnesota
GSK Investigational Site
Rochester, Minnesota, United States, 55905
United States, Missouri
GSK Investigational Site
Lee's Summit, Missouri, United States, 64064
GSK Investigational Site
Mexico, Missouri, United States, 65265-3726
United States, New York
GSK Investigational Site
Brooklyn, New York, United States, 11206
GSK Investigational Site
East Setauket, New York, United States, 11733-9292
GSK Investigational Site
Great Neck, New York, United States, 11021
GSK Investigational Site
Lake Success, New York, United States, 11042
United States, North Carolina
GSK Investigational Site
Chapel Hill, North Carolina, United States, 27599-7080
GSK Investigational Site
Charlotte, North Carolina, United States, 28207
GSK Investigational Site
Charlotte, North Carolina, United States, 28209
GSK Investigational Site
Durham, North Carolina, United States, 27710
GSK Investigational Site
Raleigh, North Carolina, United States, 27612
United States, Ohio
GSK Investigational Site
Columbus, Ohio, United States, 43215
United States, Oklahoma
GSK Investigational Site
Tulsa, Oklahoma, United States, 74135
United States, Oregon
GSK Investigational Site
Portland, Oregon, United States, 97225
United States, Pennsylvania
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15212
United States, Tennessee
GSK Investigational Site
Germantown, Tennessee, United States, 38138
GSK Investigational Site
Nashville, Tennessee, United States, 37212-1610
United States, Utah
GSK Investigational Site
Ogden, Utah, United States, 84405
United States, Virginia
GSK Investigational Site
Christiansburg, Virginia, United States, 24073
GSK Investigational Site
Danville, Virginia, United States, 24541
GSK Investigational Site
Norfolk, Virginia, United States, 23502
GSK Investigational Site
Richmond, Virginia, United States, 23249
United States, Washington
GSK Investigational Site
Seattle, Washington, United States, 98195
GSK Investigational Site
Seattle, Washington, United States, 98101
United States, Wisconsin
GSK Investigational Site
Madison, Wisconsin, United States, 53792
GSK Investigational Site
Milwaukee, Wisconsin, United States, 53226
Australia, New South Wales
GSK Investigational Site
Bankstown, New South Wales, Australia, 2200
Australia, Queensland
GSK Investigational Site
Hersten, Queensland, Australia, 4029
Australia, South Australia
GSK Investigational Site
Adelaide, South Australia, Australia, 5000
GSK Investigational Site
Kurralta Park, South Australia, Australia, 5037
Australia, Victoria
GSK Investigational Site
Box Hill, Victoria, Australia, 3128
GSK Investigational Site
Fitzroy, Victoria, Australia, 3065
GSK Investigational Site
Prahran, Victoria, Australia, 3181
Australia, Western Australia
GSK Investigational Site
Fremantle, Western Australia, Australia, 6160
Austria
GSK Investigational Site
Hall in Tirol, Austria, 6060
GSK Investigational Site
Linz, Austria, A-4021
GSK Investigational Site
Oberpullendorf, Austria, 7350
GSK Investigational Site
St.Veit/Glan, Austria, 9300
GSK Investigational Site
Wien, Austria, 1050
GSK Investigational Site
Wien, Austria, 1030
GSK Investigational Site
Wien, Austria, 1090
Belgium
GSK Investigational Site
Bonheiden, Belgium, 2820
GSK Investigational Site
Brussels, Belgium, 1000
GSK Investigational Site
Brussels, Belgium, 1200
GSK Investigational Site
Gent, Belgium, 9000
GSK Investigational Site
Kortrijk, Belgium, 8500
GSK Investigational Site
Leuven, Belgium, 3000
GSK Investigational Site
Roeselare, Belgium, 8800
Bulgaria
GSK Investigational Site
Plovdiv, Bulgaria, 4002
GSK Investigational Site
Sofia, Bulgaria, 1407
GSK Investigational Site
Sofia, Bulgaria, 1527
GSK Investigational Site
Sofia, Bulgaria, 1431
GSK Investigational Site
Varna, Bulgaria, 9010
Canada, Alberta
GSK Investigational Site
Calgary, Alberta, Canada, T2N 4Z6
GSK Investigational Site
Edmonton, Alberta, Canada, T6G 2X8
Canada, British Columbia
GSK Investigational Site
Abbotsford, British Columbia, Canada, V2S 3N5
GSK Investigational Site
Vancouver, British Columbia, Canada, V6Z 2K5
Canada, Manitoba
GSK Investigational Site
Winnipeg, Manitoba, Canada, R3A 1R9
Canada, Nova Scotia
GSK Investigational Site
Halifax, Nova Scotia, Canada, B3H 2Y9
Canada, Ontario
GSK Investigational Site
Hamilton, Ontario, Canada, L8N 4A6
GSK Investigational Site
Hamilton, Ontario, Canada, L8N 3Z5
GSK Investigational Site
Kingston, Ontario, Canada, K7L 5G2
GSK Investigational Site
London, Ontario, Canada, N6A 5A5
GSK Investigational Site
London, Ontario, Canada, N6A 5W9
GSK Investigational Site
Ottawa, Ontario, Canada, K1H 1A2
Canada, Quebec
GSK Investigational Site
Montreal, Quebec, Canada, H3T 1E2
GSK Investigational Site
Montreal, Quebec, Canada, H3A 1A1
Canada
GSK Investigational Site
Quebec, Canada, G1S 4L8
GSK Investigational Site
Quebec, Canada, G3K 2P8
Chile
GSK Investigational Site
Vina del Mar, Chile, 2520012
Czech Republic
GSK Investigational Site
Hradec Králové, Czech Republic, 500 12
GSK Investigational Site
Olomouc, Czech Republic, 77520
GSK Investigational Site
Ostrava - Vitkovice, Czech Republic, 70384
GSK Investigational Site
Praha 10, Czech Republic, 100 34
GSK Investigational Site
Praha 4, Czech Republic, 140 21
GSK Investigational Site
Praha 7, Czech Republic, 17004
GSK Investigational Site
Praha 9, Czech Republic, 190 00
Denmark
GSK Investigational Site
Aalborg, Denmark, 9000
GSK Investigational Site
Aarhus, Denmark, 8000
GSK Investigational Site
Herlev, Denmark, 2730
GSK Investigational Site
Hvidovre, Denmark, 2605
GSK Investigational Site
Odense, Denmark, 5000
Estonia
GSK Investigational Site
Tallinn, Estonia, 10617
GSK Investigational Site
Tallinn, Estonia, EE-10138
GSK Investigational Site
Tartu, Estonia, 51014
France
GSK Investigational Site
Clichy cedex, France, 92118
GSK Investigational Site
Lille cedex, France, 59037
GSK Investigational Site
Nantes cedex 1, France, 44093
GSK Investigational Site
Nice cedex 3, France, 06202
GSK Investigational Site
Paris cedex 10, France, 75475
GSK Investigational Site
Pessac cedex, France, 33604
GSK Investigational Site
Saint-Priest en Jarez, France, 42270
GSK Investigational Site
Vandoeuvre Les Nancy, France, 54511
Germany
GSK Investigational Site
Ulm, Baden-Wuerttemberg, Germany, 89081
GSK Investigational Site
Frankfurt am Main, Hessen, Germany, 60590
GSK Investigational Site
Brinkum/Stuhr, Niedersachsen, Germany, 28816
GSK Investigational Site
Hannover, Niedersachsen, Germany, 30625
GSK Investigational Site
Minden, Nordrhein-Westfalen, Germany, 32423
GSK Investigational Site
Berlin, Germany, 13353
GSK Investigational Site
Berlin, Germany, 10117
GSK Investigational Site
Hamburg, Germany, 22559
GSK Investigational Site
Hamburg, Germany, 20148
Hong Kong
GSK Investigational Site
Hong Kong, Hong Kong
GSK Investigational Site
Shatin, New Territories, Hong Kong
Hungary
GSK Investigational Site
Bekescsaba, Hungary, 5600
GSK Investigational Site
Budapest, Hungary, 1062
GSK Investigational Site
Budapest, Hungary, 1136
GSK Investigational Site
Budapest, Hungary, 1083
GSK Investigational Site
Debrecen, Hungary, 4025
GSK Investigational Site
Mosonmagyaróvár, Hungary, 9200
GSK Investigational Site
Szekszárd, Hungary, 7100
GSK Investigational Site
Vác, Hungary, 2600
Israel
GSK Investigational Site
Afula, Israel, 18101
GSK Investigational Site
Beer Sheva, Israel, 84101
GSK Investigational Site
Haifa, Israel, 31096
GSK Investigational Site
Holon, Israel, 58100
GSK Investigational Site
Jerusalem, Israel, 91031
GSK Investigational Site
Jerusalem, Israel, 91120
GSK Investigational Site
Kfar Saba, Israel, 44281
GSK Investigational Site
Petah Tikva, Israel, 49100
GSK Investigational Site
Ramat-Gan, Israel, 52621
GSK Investigational Site
Tel Aviv, Israel, 64239
GSK Investigational Site
Zerifin, Israel, 70300
Italy
GSK Investigational Site
Palermo, Sicilia, Italy, 90127
GSK Investigational Site
Genova, Italy, 16132
GSK Investigational Site
Modena, Italy, 41100
GSK Investigational Site
Roma, Italy, 00152
GSK Investigational Site
Roma, Italy, 00168
Japan
GSK Investigational Site
Aichi, Japan, 460-0012
GSK Investigational Site
Chiba, Japan, 285-8741
GSK Investigational Site
Fukuoka, Japan, 818-8502
GSK Investigational Site
Fukuoka, Japan, 812-8582
GSK Investigational Site
Hiroshima, Japan, 720-8520
GSK Investigational Site
Hokkaido, Japan, 060-0033
GSK Investigational Site
Hyogo, Japan, 663-8501
GSK Investigational Site
Kagoshima, Japan, 892-8512
GSK Investigational Site
Kagoshima, Japan, 892-0846
GSK Investigational Site
Miyagi, Japan, 981-3213
GSK Investigational Site
Osaka, Japan, 530-0011
GSK Investigational Site
Osaka, Japan, 545-8586
GSK Investigational Site
Tokyo, Japan, 160-8582
GSK Investigational Site
Tokyo, Japan, 169-0073
Korea, Republic of
GSK Investigational Site
Daegu, Korea, Republic of, 705-717
GSK Investigational Site
Pusan, Korea, Republic of, 602-739
GSK Investigational Site
Seoul, Korea, Republic of, 138-736
GSK Investigational Site
Seoul, Korea, Republic of, 130702
GSK Investigational Site
Seoul, Korea, Republic of, 135710
GSK Investigational Site
Seoul, Korea, Republic of, 120-752
GSK Investigational Site
Wonju, Korea, Republic of, 220701
Netherlands
GSK Investigational Site
Amsterdam, Netherlands, 1105 AZ
GSK Investigational Site
Amsterdam, Netherlands, 1091 AC
GSK Investigational Site
Amsterdam, Netherlands, 1081 HV
GSK Investigational Site
EDE, Netherlands, 6716 RP
GSK Investigational Site
Eindhoven, Netherlands, 5623 EJ
GSK Investigational Site
Rotterdam, Netherlands, 3083 AN
GSK Investigational Site
Rotterdam, Netherlands, 3015 CE
New Zealand
GSK Investigational Site
Dunedin, New Zealand, 9054
GSK Investigational Site
Lower Hutt, New Zealand, 6007
GSK Investigational Site
Otahuhu, Auckland, New Zealand, 2025
GSK Investigational Site
Tauranga., New Zealand, 3143
Norway
GSK Investigational Site
Tromsø, Norway, 9038
GSK Investigational Site
Tønsberg, Norway, 3116
Poland
GSK Investigational Site
Bydgoszcz, Poland, 85-168
GSK Investigational Site
Bydgoszcz, Poland, 85-681
GSK Investigational Site
Lublin, Poland, 20-582
GSK Investigational Site
Sopot, Poland, 81-756
GSK Investigational Site
Torun, Poland, 87-100
GSK Investigational Site
Wroclaw, Poland, 53-333
Portugal
GSK Investigational Site
Lisboa, Portugal, 1769-001
GSK Investigational Site
Lisboa, Portugal, 1649-035
GSK Investigational Site
Porto, Portugal, 4099-001
GSK Investigational Site
Viseu, Portugal, 3504-509
Russian Federation
GSK Investigational Site
Irkutsk, Russian Federation, 664079
GSK Investigational Site
Kazan, Russian Federation, 420064
GSK Investigational Site
Lipetsk, Russian Federation, 398055
GSK Investigational Site
Moscow, Russian Federation, 129110
GSK Investigational Site
Nizhniy Novgorod, Russian Federation, 603126
GSK Investigational Site
Rostov-on-Don, Russian Federation, 344091
GSK Investigational Site
Samara, Russian Federation, 443011
GSK Investigational Site
St. Petersburg, Russian Federation, 196247
GSK Investigational Site
St. Petersburg, Russian Federation, 197047
GSK Investigational Site
Tomsk, Russian Federation, 634063
Slovakia
GSK Investigational Site
Bratislava, Slovakia, 851 01
GSK Investigational Site
Bratislava, Slovakia, 851 07
GSK Investigational Site
Bratislava, Slovakia, 831 04
GSK Investigational Site
Nitra, Slovakia, 949 01
GSK Investigational Site
Nove Mesto nad Vahom, Slovakia, 915 01
GSK Investigational Site
Presov, Slovakia, 080 01
GSK Investigational Site
Trnava, Slovakia, 917 02
South Africa
GSK Investigational Site
Bellville, South Africa, 7530
GSK Investigational Site
Claremont, South Africa, 7708
GSK Investigational Site
Observatory, South Africa, 7925
GSK Investigational Site
Parktown, South Africa, 2192
Spain
GSK Investigational Site
Badalona, Spain, 08916
GSK Investigational Site
Elche, Spain, 03293
GSK Investigational Site
Fuenlabrada (Madrid), Spain, 28942
GSK Investigational Site
Galdakao/Vizcaya, Spain, 48960
GSK Investigational Site
Madrid, Spain, 28040
GSK Investigational Site
Madrid, Spain, 28007
GSK Investigational Site
Madrid, Spain, 28046
GSK Investigational Site
Madrid, Spain, 28006
GSK Investigational Site
Marbella, Spain, 29600
GSK Investigational Site
Sabadell (Barcelona), Spain, 08208
GSK Investigational Site
Santander, Spain, 39008
Sweden
GSK Investigational Site
Lund, Sweden, SE-221 85
GSK Investigational Site
Stockholm, Sweden, SE-171 76
GSK Investigational Site
Stockholm, Sweden, SE-182 88
Switzerland
GSK Investigational Site
Bern, Switzerland, 3004
GSK Investigational Site
Zürich, Switzerland, 8091
Taiwan
GSK Investigational Site
Taichung, Taiwan, 40705
Turkey
GSK Investigational Site
Ankara, Turkey, 06100
Ukraine
GSK Investigational Site
Chernivtsi, Ukraine, 58005
GSK Investigational Site
Dnipropetrovsk, Ukraine, 49044
GSK Investigational Site
Donetsk, Ukraine, 83003
GSK Investigational Site
Donetsk, Ukraine, 83017
GSK Investigational Site
Kharkiv, Ukraine, 61037
GSK Investigational Site
Kyiv, Ukraine
GSK Investigational Site
Odesa, Ukraine, 65117
GSK Investigational Site
Simferopol, Ukraine, 95017
GSK Investigational Site
Vinnytsya, Ukraine, 21029
United Kingdom
GSK Investigational Site
Harrow, Middlesex, United Kingdom, HA1 3UJ
GSK Investigational Site
Birmingham, United Kingdom, B9 5SS
GSK Investigational Site
Bristol, United Kingdom, BS2 8HW
GSK Investigational Site
Edinburgh, United Kingdom, EH4 2XU
GSK Investigational Site
Manchester, United Kingdom, M13 9WL
GSK Investigational Site
Newcastle-upon-Tyne, United Kingdom, NE1 4LP
GSK Investigational Site
Oxford, United Kingdom, OX3 9DU
GSK Investigational Site
Salford, United Kingdom, M6 8HD
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01316939     History of Changes
Other Study ID Numbers: 114157, 2010-022383-12
Study First Received: March 3, 2011
Last Updated: March 13, 2014
Health Authority: Australia: Human Research Ethics Committee
Canada: Health Canada
Belgium: Federal Agency for Medicines and Health Products, FAMHP
United States: Food and Drug Administration
Norway: Norwegian Medicines Agency
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Germany: Bundesinstitut für Arzneimittel und Medizinprodukte
Denmark: Danish Medicines Agency
Japan: Pharmaceuticals and Medical Devices Agency
Sweden: Medical Products Agency
Europe: European Medicines Agency

Keywords provided by GlaxoSmithKline:
Crohn's disease, oral CCR9 antagonist, placebo-controlled, maintenance of remission, 52-week treatment, quality of life

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases

ClinicalTrials.gov processed this record on April 15, 2014